ViaDerma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VDRM research report →
Companyviadermalicensing.com
ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. It focuses on developing and marketing pharmaceutical products, as well as licensing its technology to companies in the pharmaceutical industry in various therapeutic areas.
- CEO
- Christopher A Otiko
- IPO
- 2014
- Employees
- 75
- HQ
- Marina del Rey, CA, US
Price Chart
Valuation
- Market Cap
- $493.48K
- P/E
- 114.97
- P/S
- 0.82
- P/B
- 3.82
- EV/EBITDA
- 9.99
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.97%
- Op Margin
- 30.85%
- Net Margin
- 0.68%
- ROE
- -0.48%
- ROIC
- 41.53%
Growth & Income
- Revenue
- $600.50K · 11.07%
- Net Income
- $4.10K · -99.31%
- EPS
- $0.00 · -100.00%
- Op Income
- $185.27K
- FCF YoY
- 111.73%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.15
- Avg Volume
- 73.32K
Get TickerSpark's AI analysis on VDRM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VDRM Coverage
We haven't published any research on VDRM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VDRM Report →